A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics
about
Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models.A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facilityResearch and development of antibiotics: insights from patents and citation network.The long and winding road to inhaled TB therapy: not only the bug's fault.Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.Toolbox for Antibiotics Discovery from Microorganisms.What if there were no new antibiotics? A look at alternatives.Identification of the Biosynthesis Gene Cluster for the Novel Lantibiotic Paenilan from Paenibacillus polymyxa E681 and Characterization of its Product.Institutional profile: Community for Open Antimicrobial Drug Discovery - crowdsourcing new antibiotics and antifungals.Antimicrobial agents - optimising the ecological balance.Mapping global policy discourse on antimicrobial resistance.Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations.Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model.
P2860
Q30151817-6DF862C5-56A8-4BC1-A2AF-F9D91061987BQ33571968-0006E9A5-18CF-4B8D-9C99-76156BF2FCC2Q36715154-9BD0BD99-DCAE-4B84-B730-BF5C8DA03E71Q38778154-93838526-F8A9-4922-BE39-38049662A75FQ38782463-0B4210FD-0D1E-45C9-BADF-49F730750E1BQ38793981-EDBA4A75-39C0-4289-AD81-931635CC7F97Q38867326-C59DA974-309C-4301-B73A-7C0627CE7045Q38966367-1F3FB772-A2D6-4FFB-95C0-9818C6F14E11Q40067898-EE0156FD-2B3C-4181-9FD2-C0D46A74872BQ42335280-A2893542-2248-4634-82FC-DA5CFB3A1CE9Q42376673-C6DE60D3-DBE2-485A-9F46-6040459A7AB7Q47161178-12248C45-9C42-4E3C-9944-0AA8887F1162Q48564199-697A7850-1FB1-4713-9AEC-FA7EFDAA1865Q52355825-E1D83A5A-8E4A-43E3-BAE5-071B095B96A7Q52597584-87454905-B2A9-4A25-9CF1-402F7E72DA52Q53690104-1D10FB3D-9C3F-4B77-BFBD-1403E352E274
P2860
A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
A systematic review and critic ...... velopment of novel antibiotics
@ast
A systematic review and critic ...... velopment of novel antibiotics
@en
A systematic review and critic ...... velopment of novel antibiotics
@nl
type
label
A systematic review and critic ...... velopment of novel antibiotics
@ast
A systematic review and critic ...... velopment of novel antibiotics
@en
A systematic review and critic ...... velopment of novel antibiotics
@nl
prefLabel
A systematic review and critic ...... velopment of novel antibiotics
@ast
A systematic review and critic ...... velopment of novel antibiotics
@en
A systematic review and critic ...... velopment of novel antibiotics
@nl
P2093
P2860
P31
P921
P3181
P356
P1476
A systematic review and critic ...... velopment of novel antibiotics
@en
P2093
David M Brogan
Elias Mossialos
Matthew J Renwick
P2860
P2888
P3181
P356
10.1038/JA.2015.98
P407
P577
2016-02-01T00:00:00Z
P5875
P6179
1027730298